Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.62 |
| ▸ | GAA | P10253 | 9/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | GFER | P55789 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11742148 | 0.85 | MAPT (0.59) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL13937042 | 0.81 | KDM4E (0.56) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL16657381 | 0.81 | RAD52 (0.50) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL8693690 | 0.80 | MAPT (0.63) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL8465011 | 0.80 | MAPT (0.66) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL656253 | 0.80 | GAA (0.69) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL13042657 | 0.80 | RAB9A (0.59) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL27618345 | 0.80 | MAPK14 (0.43) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL5084625 | 0.79 | MAPT (0.67) | MAPTGAAKDM4EALDH1A1MEN1 | |
| SCHEMBL8430768 | 0.78 | MAPT (0.56) | MAPTGAAKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103476767-B | Heterocyclic compounds as PI3 kinase inhibitors | HOFFMANN LA ROCHE | 2015-06-10 | — | — | CN | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| EP-2673269-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-8063230-B1 | Tris(N-aryl benzimidazole)benzenes and their use in electronic devices | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1789050-A1 | NOVEL QUINOXALINONE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006016278-A1 | NOVEL QUINOXALINONE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030566-A1 | Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY, LLC | 2006-02-09 | — | — | US | disclosed |
| EP-0558104-B1 | 1,5-Benzodiazepine derivatives and their use in medicine | GLAXO WELLCOME SPA (IT) | 1998-07-29 | — | — | EP | disclosed |
| EP-0623118-B1 | CARBAMATE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO WELLCOME SPA (IT) | 1998-05-13 | — | — | EP | disclosed |
| US-5637697-A | ANTAGONIST TO GASTRIN AND(OR) CHLOROCYSTOKININ | GLAXO SPA (IT) | 1997-06-10 | — | — | US | disclosed |
| US-5580895-A | GASTROINTESTINAL OR CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO SPA (IT) | 1996-12-03 | — | — | US | disclosed |
| US-5486514-A | GASTRIN, CHOLECYSTOKININ RECEPTOR ANTAGONISTS | GLAXO SPA (IT) | 1996-01-23 | — | — | US | disclosed |
| EP-0623118-A1 | CARBAMATE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO S.p.A. (IT) | 1994-11-09 | — | — | EP | disclosed |
| EP-0558104-A1 | 1,5-Benzodiazepine derivatives and their use in medicine | GLAXO S.p.A. (IT) | 1993-09-01 | — | — | EP | disclosed |
| WO-1993014074-A1 | 1,5-BENZODIAZEPINE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO SPA (IT) | 1993-07-22 | — | — | WO | disclosed |
| WO-1993014075-A1 | CARBAMATE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO SPA (IT) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030566-A1 | Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | SLC6A2, SLC18A2, SLC6A3 | MAPT 837/4885GAA 2010/4885KDM4E 1317/4885 |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | MAPT 1752/4885GAA 1526/4885KDM4E 4269/4885 |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | MAPT 97/4885GAA 525/4885KDM4E 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.